Zai Lab Limited splits its revenue into 8 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Zejula at $189.0 million, 41% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
436
|
457
|
398
|
267
|
213
|
144
|
49
|
13
|
0
|
—
|
| Zejula |
—
|
189
+1.0%
share 41.3%
|
187
+10.8%
share 47.1%
|
169
+16.3%
share 63.3%
|
145
+55.2%
share 68.3%
|
94
+191.2%
share 64.9%
|
32
+385.1%
share 65.6%
|
7
share 51.0%
|
—
|
—
|
| Vyvgart Vyvgart Hytrulo |
—
|
94
+0.6%
share 20.6%
|
94
+835.4%
share 23.6%
|
10
share 3.8%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Nuzyra |
—
|
61
share 13.3%
|
—
|
22
+316.5%
share 8.1%
|
5
+173233.3%
share 2.4%
|
0
share 0.0%
|
—
|
—
|
—
|
—
|
| Optune |
—
|
48
+19.4%
share 10.6%
|
40
-13.8%
share 10.2%
|
47
-0.7%
share 17.6%
|
47
+21.6%
share 22.3%
|
39
+137.0%
share 27.0%
|
16
+158.1%
share 33.5%
|
6
share 49.0%
|
—
|
—
|
| Qinlock |
—
|
36
+23.5%
share 7.8%
|
29
+49.8%
share 7.2%
|
19
+28.6%
share 7.2%
|
15
+28.7%
share 7.0%
|
12
+2790.5%
share 8.1%
|
0
share 0.8%
|
—
|
—
|
—
|
| XACDURO |
—
|
23
+593.3%
share 5.0%
|
3
share 0.8%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| AUGTYRO |
—
|
6
+409.0%
share 1.2%
|
1
share 0.3%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Product And Service Other |
—
|
1
share 0.2%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZLAB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Shanghai
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1704292
- Former names
- Zai Lab Ltd (until Oct 23, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.